ALEXANDRIA, Va., Feb. 5 -- United States Patent no. 12,213,988, issued on Feb. 4, was assigned to AstraZeneca AB (Sodertalje, Sweden).
"Methods of treating chronic kidney disease with dapagliflozin" was invented by Anna Maria Langkilde (Sodertalje, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin."
The patent was filed on June 14, 2021, under Application No. 17/347,230.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fne...